Riskpilot← Back to searchSign inGet full accessFinnpharma Oy
OYActiveY-tunnus 2332464-9Kestilänraitti 4Retail sale of medical and orthopaedic goods · NACE 4774Est. 20101 employees
Revenue 2024
EUR 2,2M
EBITDA margin
6.7%
Equity ratio
62.9%
Financial strength
Net profit 2024
EUR 104K
1 employees
| Revenue | EUR 2,2M | — |
| EBITDA | EUR 145K | — |
| Net profit | EUR 104K | — |
| Total assets | EUR 526K | +11% |
| Equity | EUR 331K | — |
| Employees | 1 | — |
Legal name
Finnpharma Oy
Y-tunnus number
2332464-9
Legal form
Osakeyhtiö
NACE code
4774 · Retail sale of medical and orthopaedic goods
Founded
23. huhtikuuta 2010
Share capital
EUR 2 500
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on terveys- ja eläinterveystuotteiden sekä hygieniavalmisteiden maahantuonti, myynti ja markkinointi, lääkealan ja eläinterveyden konsultointi.
Address
Kestilänraitti 4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenue | 748 | 1 670 | 1 702 | 2 018 | 0 | 2 171 |
| Staff expenses | −34 | −162 | −283 | −328 | −0 | −381 |
| EBITDA | −48 | 56 | 95 | 199 | 0 | 145 |
| Depreciation & amort. | −9 | −22 | −42 | −23 | −0 | −13 |
| EBIT | −57 | 34 | 54 | 176 | 0 | 132 |
| Net financials | −2 | −2 | −2 | −3 | 0 | 0 |
| Profit before tax | −59 | 32 | 52 | 173 | 0 | 132 |
| Tax | 0 | 6 | 4 | 29 | −0 | 28 |
| Net profit | −60 | 26 | 48 | 144 | 0 | 104 |
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Total assets | 193 | 316 | 324 | 501 | 473 | 526 |
| Equity | 36 | 133 | 122 | 254 | 0 | 331 |
| Long-term debt | 33 | 32 | 120 | 40 | 2 702 | 1 |
| Short-term debt | 42 | 151 | 82 | 207 | 0 | 185 |
| Total debt | 75 | 183 | 202 | 247 | 2 702 | 186 |
EBITDA margin
6.7%
This company
15.8%
Market median
-58% vs market
20192024
Equity ratio
62.9%
This company
38.2%
Market median
+65% vs market
20192024
Return on equity
31.3%
This company
18.4%
Market median
+70% vs market
20192024
Net profit margin
4.8%
This company
8.1%
Market median
-41% vs market
20192024
Asset turnover
4.12×
This company
1.12×
Market median
+268% vs market
20192024
Debt / equity
0.59×
This company
0.62×
Market median
+5% vs market
20192024
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via PRH / YTJ · Period 2019-01-01 – 2019-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
NH Deputy Member | Deputy Member | 2010 | — | — |
SE Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
HM Chief Executive Officer | Chief Executive Officer | 2010 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2010 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Finnpharma Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Noora Henriikka Taipaleenmäki | Deputy Member | 0 companies |
| Sonja Elina Taipaleenmäki | Chief Executive Officer | 0 companies |
| Hanna Maaria Taipaleenmäki | Chief Executive Officer | 0 companies |
| Seppo Olavi Taipaleenmäki | Board of Directors | 0 companies |